Nasdaq · Healthcare
Cytosorbents Corp (CTSO)
As-reported financials and recent SEC filings for Cytosorbents Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$37.1M
Net income
$-8.2M
Net margin
-22.1%
Diluted EPS
$-0.13
ROE
-138.9%
P/E (TTM)
—
Market cap
—
Debt / equity
2.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M |
| Operating income | $-14.7M | $-16.5M | $-31.9M | $-31.5M | $-22.7M |
| Net income | $-8.2M | $-20.7M | $-29.2M | $-32.8M | $-24.6M |
| Diluted EPS | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →ARS2026-06-25
View on EDGAR →DEFA14A2026-06-25
View on EDGAR →DEF 14A2026-06-25
View on EDGAR →8-K2026-06-25
View on EDGAR →42026-06-16
View on EDGAR →42026-06-15
View on EDGAR →PRE 14A2026-06-11
View on EDGAR →Largest Healthcare peers
Go deeper on CTSO
Search Cytosorbents Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.